Cancer name Hepatocellular Carcinoma
Cancer Type LIHC
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment CCR2 antagonist
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature Ly6C high cells
Official Symbol NA
Mode of action CE_D_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Treatment with theCCR2 antagonist caused a decrease in the number of blood Ly6C high in flammatory monocytes and a slight decrease of Ly6C low non-inflammatory monocytes, but increased the numbers of CD8+ and CD4+T cells in Hepa1-6 and LPC-H12 HCC models.
PMID 26452628
Title Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.